



Review

Comprehensive review on lactate metabolism in human health ☆☆☆



M. Adeva-Andany ^{a,*}, M. López-Ojén ^b, R. Funcasta-Calderón ^{a,1}, E. Ameneiros-Rodríguez ^{a,1},
C. Donapetry-García ^{a,1}, M. Vila-Altesor ^{a,1}, J. Rodríguez-Seijas ^{a,1}

^a Nephrology Division, Hospital General Juan Cardona, Ave. Pardo Bazán, s/n, 15406 Ferrol, La Coruña, Spain

^b Internal Medicine Division, Policlínica Assistens, c/Federico García, 4-planta baja, 15009 La Coruña, Spain

ARTICLE INFO

Article history:

Received 18 October 2013

Received in revised form 19 March 2014

Accepted 5 May 2014

Available online 12 June 2014

Keywords:

Glycolysis

Tricarboxylic acid cycle

Respiratory chain

Gluconeogenesis

Insulin resistance

Diabetes mellitus

ABSTRACT

Metabolic pathways involved in lactate metabolism are important to understand the physiological response to exercise and the pathogenesis of prevalent diseases such as diabetes and cancer. Monocarboxylate transporters are being investigated as potential targets for diagnosis and therapy of these and other disorders. Glucose and alanine produce pyruvate which is reduced to lactate by lactate dehydrogenase in the cytoplasm without oxygen consumption. Lactate removal takes place via its oxidation to pyruvate by lactate dehydrogenase. Pyruvate may be either oxidized to carbon dioxide producing energy or transformed into glucose. Pyruvate oxidation requires oxygen supply and the cooperation of pyruvate dehydrogenase, the tricarboxylic acid cycle, and the mitochondrial respiratory chain. Enzymes of the gluconeogenesis pathway sequentially convert pyruvate into glucose. Congenital or acquired deficiency on gluconeogenesis or pyruvate oxidation, including tissue hypoxia, may induce lactate accumulation. Both obese individuals and patients with diabetes show elevated plasma lactate concentration compared to healthy subjects, but there is no conclusive evidence of hyperlactatemia causing insulin resistance. Available evidence suggests an association between defective mitochondrial oxidative capacity in the pancreatic β -cells and diminished insulin secretion that may trigger the development of diabetes in patients already affected with insulin resistance. Several mutations in the mitochondrial DNA are associated with diabetes mellitus, although the pathogenesis remains unsettled. Mitochondrial DNA mutations have been detected in a number of human cancers. D-lactate is a lactate enantiomer normally formed during glycolysis. Excess D-lactate is generated in diabetes, particularly during diabetic ketoacidosis. D-lactic acidosis is typically associated with small bowel resection.

© 2014 Elsevier B.V. and Mitochondria Research Society. All rights reserved.

Contents

1.	Introduction	78
2.	L-lactate metabolism	78
2.1.	Metabolic pathways involved in L-lactate formation	78
2.1.1.	L-lactate formation from alanine	78
2.1.2.	L-lactate formation from glucose	78
2.2.	Metabolic pathways involved in L-lactate clearance	79
2.2.1.	Oxidative metabolism of pyruvate	79
2.2.2.	The gluconeogenesis pathway	80
3.	D-lactate metabolism	80

Abbreviations: ADP, adenosine diphosphate; ALT, alanine aminotransferase; ATP, adenosine triphosphate; CoA, coenzyme A; FAD, flavin adenine dinucleotide; FADH₂, reduced flavin adenine dinucleotide; GPT, glutamate pyruvate transaminase; HIV, human immunodeficiency virus; LDH, lactate dehydrogenase; MELAS, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes syndrome; MCT, proton-coupled monocarboxylate transporter; MIDD, maternally inherited diabetes mellitus and deafness; NAD⁺, oxidized nicotinamide adenine dinucleotide; NADH, reduced nicotinamide adenine dinucleotide; NADPH, reduced nicotinamide adenine dinucleotide phosphate; NRTI, nucleoside analogs reverse transcriptase inhibitors; PDH, pyruvate dehydrogenase; PEPCK, phosphoenolpyruvate carboxykinase; SMCT, sodium-linked monocarboxylate transporter; TCA, tricarboxylic acid; T2D, type 2 diabetes mellitus.

☆ There was no financial support for this work.

☆☆ The authors declare that they have no conflict of interest.

* Corresponding author. Tel.: +34 664 527 257, +34 981 31 25 00.

E-mail address: madevaa@yahoo.com (M. Adeva-Andany).

¹ Tel.: +34 981 31 25 00.

4.	Lactate transport across plasma membranes in the human body	80
4.1.	Proton-coupled monocarboxylate transporters (MCTs)	80
4.1.1.	Substrates and transport mechanism of proton-linked monocarboxylate transporters	80
4.1.2.	Human genes encoding proton-linked monocarboxylate transporters	81
4.1.3.	Human tissue expression of proton-linked monocarboxylate transporters	81
4.1.4.	Regulation of proton-coupled monocarboxylate transporters	81
4.1.5.	Potential role of proton-coupled monocarboxylate transporters on human cancer	81
4.2.	Sodium-coupled monocarboxylate transporters	81
4.2.1.	SMCT1 (SLC5A8)	81
4.2.2.	SMCT2 (SLC5A12)	82
5.	Lactate handling by different human tissues	82
5.1.	Lactate handling by skeletal muscle	82
5.1.1.	Resting skeletal muscle	82
5.1.2.	Active skeletal muscle	82
5.1.3.	Physiological response to exercise-induced hyperlactatemia	82
5.1.4.	Effect of training on skeletal muscle lactate production and transport	82
5.1.5.	Lactate production by skeletal muscle and oxygen delivery	82
5.2.	Lactate handling by the human heart	83
5.3.	Lactate handling by the human brain	83
5.4.	Lactate handling by the human liver	83
5.5.	Lactate handling by the human kidney	84
5.6.	Lactate handling by the human adipose tissue	84
5.7.	Lactate handling by the human lung	84
5.8.	Lactate handling by human blood cells	84
6.	Interorgan flow of lactate	84
7.	Insulin resistance and lactate metabolism in humans	85
7.1.	Glucose metabolism and lactate formation in healthy humans	85
7.1.1.	Lactate metabolism in response to glucose or insulin challenge	85
7.1.2.	Tissues responsible for the hyperlactatemia associated with glucose or insulin challenge	85
7.2.	Obesity and lactate metabolism in humans	86
7.2.1.	Glucose metabolism in obesity and lactate formation	86
7.2.2.	Fasting plasma lactate concentration in obesity	86
7.2.3.	Lactate metabolism in response to glucose or insulin challenge in obesity	86
7.2.4.	Tissues responsible for obesity-associated hyperlactatemia	86
7.3.	Diabetes mellitus and lactate metabolism in humans	87
7.3.1.	Glucose metabolism in diabetes and lactate formation	87
7.3.2.	Fasting plasma lactate concentration in diabetes mellitus	87
7.3.3.	Lactate metabolism in response to glucose or insulin challenge in diabetes mellitus	87
7.3.4.	Tissues responsible for diabetes-associated hyperlactatemia	87
7.3.5.	Role of the mitochondrial dysfunction in the diabetes-associated hyperlactatemia	88
7.3.6.	Diabetes caused by mitochondrial DNA mutations	89
8.	Causes of L-lactic acidosis	89
8.1.	Pyruvate transport inside the mitochondrial network	90
8.2.	Pyruvate dehydrogenase complex deficiency	90
8.3.	Tricarboxylic acid cycle dysfunction	90
8.4.	Congenital mitochondrial respiratory chain dysfunction	90
8.5.	Acquired mitochondrial respiratory chain dysfunction	90
8.5.1.	Carbon monoxide poisoning	90
8.5.2.	Cyanide poisoning	91
8.5.3.	Drugs	91
8.6.	Defective gluconeogenesis pathway	91
8.7.	Thiamine deficiency	92
8.8.	Alcohols	92
8.8.1.	Ethanol	92
8.8.2.	Methanol	92
8.8.3.	Propylene glycol	93
8.8.4.	Ethylene glycol	93
8.9.	Fructose	93
8.10.	Malignancy	93
8.11.	Liver disease	94
8.12.	Sepsis	94
8.13.	Asthma	94
8.14.	Other causes of L-lactic acidosis	94
9.	D-lactic acidosis	94
10.	Summary	94
	Acknowledgment	95
	References	95

Download English Version:

<https://daneshyari.com/en/article/8399389>

Download Persian Version:

<https://daneshyari.com/article/8399389>

[Daneshyari.com](https://daneshyari.com)